BR112022003762A2 - Therapeutic fusion proteins - Google Patents
Therapeutic fusion proteinsInfo
- Publication number
- BR112022003762A2 BR112022003762A2 BR112022003762A BR112022003762A BR112022003762A2 BR 112022003762 A2 BR112022003762 A2 BR 112022003762A2 BR 112022003762 A BR112022003762 A BR 112022003762A BR 112022003762 A BR112022003762 A BR 112022003762A BR 112022003762 A2 BR112022003762 A2 BR 112022003762A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- acute
- chronic
- organ
- injuries
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000001154 acute effect Effects 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 206010038687 Respiratory distress Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000009692 acute damage Effects 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 230000009693 chronic damage Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/025—Services making use of location information using location based information parameters
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/029—Location-based management or tracking services
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Telephone Function (AREA)
Abstract
proteínas de fusão terapêuticas. a presente invenção refere-se a proteínas de fusão adequadas para uso como um medicamento ou ferramenta de pesquisa. os usos terapêuticos das proteínas de fusão podem incluir a prevenção ou o tratamento de distúrbios agudos ou crônicos inflamatórios e de órgão acionados por sistema imunológico e microvasculares, por exemplo, lesão renal aguda, infarto agudo do miocárdio, desconforto respiratório agudo ou fibrose por doença pulmonar obstrutiva crônica e outras lesões em órgãos que resultam de trauma em tecido e lesões aguda e crônica.therapeutic fusion proteins. the present invention relates to fusion proteins suitable for use as a medicament or research tool. Therapeutic uses of fusion proteins may include the prevention or treatment of acute or chronic immune-driven and microvascular organ and inflammatory disorders, e.g., acute kidney injury, acute myocardial infarction, acute respiratory distress, or fibrosis from lung disease chronic obstructive disease and other organ injuries that result from tissue trauma and acute and chronic injuries.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196045 | 2019-09-06 | ||
| PCT/IB2020/058251 WO2021044361A1 (en) | 2019-09-06 | 2020-09-04 | Therapeutic fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003762A2 true BR112022003762A2 (en) | 2022-05-31 |
Family
ID=67875416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003745A BR112022003745A2 (en) | 2019-09-06 | 2020-09-04 | Therapeutic fusion proteins |
| BR112022003762A BR112022003762A2 (en) | 2019-09-06 | 2020-09-04 | Therapeutic fusion proteins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003745A BR112022003745A2 (en) | 2019-09-06 | 2020-09-04 | Therapeutic fusion proteins |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20230220048A1 (en) |
| EP (3) | EP4025238A1 (en) |
| JP (3) | JP2022547050A (en) |
| KR (3) | KR20220058585A (en) |
| CN (3) | CN114302896A (en) |
| AR (2) | AR119902A1 (en) |
| AU (3) | AU2020343512A1 (en) |
| BR (2) | BR112022003745A2 (en) |
| CA (3) | CA3152990A1 (en) |
| CO (2) | CO2022002545A2 (en) |
| CR (2) | CR20220096A (en) |
| CU (2) | CU20220015A7 (en) |
| EC (2) | ECSP22016180A (en) |
| IL (3) | IL290618A (en) |
| JO (2) | JOP20220058A1 (en) |
| MX (2) | MX2022002637A (en) |
| PE (2) | PE20221051A1 (en) |
| TW (2) | TW202122414A (en) |
| WO (3) | WO2021044360A1 (en) |
| ZA (2) | ZA202201827B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118076371A (en) * | 2021-04-22 | 2024-05-24 | 百进生物科技公司 | Phosphatidylserine binding agents for detection and depletion of phosphatidylserine positive cells |
| CN114288386B (en) * | 2022-01-25 | 2023-12-12 | 华中科技大学同济医学院附属协和医院 | Novel Del-1 biomarker for inflammatory bowel disease and application of novel biomarker as therapeutic drug |
| WO2024080854A1 (en) * | 2022-10-14 | 2024-04-18 | Illimis Therapeutics, Inc. | Fusion molecule and method for treating immunological diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (en) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | LIPOSOMAS COUPLING METHOD. |
| ATE92107T1 (en) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS. |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| WO2006122327A2 (en) | 2005-05-13 | 2006-11-16 | The Feinstein Institute For Medical Research | Milk fat globule epidermal growth factor-factor viii and sepsis |
| CN101511866A (en) * | 2006-09-08 | 2009-08-19 | Ambrx公司 | Modified human plasma polypeptide or Fc scaffolds and their uses |
| AU2008321386B2 (en) * | 2007-11-15 | 2014-10-23 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8 |
| RU2607374C2 (en) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Versions of albumin |
| JP2013519392A (en) | 2010-02-16 | 2013-05-30 | メディミューン，エルエルシー | HSA related compositions and methods of use |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| JP2014510518A (en) | 2011-02-15 | 2014-05-01 | メディミューン，エルエルシー | HSA related compositions and methods of use |
| AU2012249539A1 (en) * | 2011-04-28 | 2013-11-14 | The Feinstein Institute For Medical Research | MFG-E8 and uses thereof |
| CN104011072B (en) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | albumin variants |
| US20140302027A1 (en) * | 2011-09-26 | 2014-10-09 | University Of Louisville Research Foundation, Inc. | Methods of treating periodontal inflammation and periodontal bone loss |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| CN105007722A (en) | 2013-02-16 | 2015-10-28 | 诺维信生物制药丹麦公司 | Pharmacokinetic animal model |
| SG11201602289WA (en) | 2013-08-23 | 2016-05-30 | Riken | Polypeptide exhibiting fluorescent properties, and utilization of same |
| MY192248A (en) * | 2014-03-31 | 2022-08-10 | Hanmi Pharm Ind Co Ltd | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
| US10911602B2 (en) * | 2014-03-31 | 2021-02-02 | British Telecommunications Public Limited Company | Data communication |
| US20170136089A1 (en) * | 2014-05-15 | 2017-05-18 | The Trustees Of The University Of Pennsylvania | Compositions and methods of regulating bone resorption |
| KR20170013621A (en) | 2015-07-28 | 2017-02-07 | (주) 넥셀 | Composition for preventing or treating tissue fibrosis by using milk fat globule-EGF factor 8 |
| CN118063619A (en) * | 2017-03-02 | 2024-05-24 | 诺华股份有限公司 | Engineered heterodimeric proteins |
| US11028139B2 (en) | 2017-05-17 | 2021-06-08 | Nexel Co., Ltd. | Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same |
| JP2022509445A (en) | 2018-10-25 | 2022-01-20 | ネクセル カンパニー，リミテッド | Compositions and Methods for Treating or Preventing Fibrosis |
-
2020
- 2020-09-04 CR CR20220096A patent/CR20220096A/en unknown
- 2020-09-04 KR KR1020227010891A patent/KR20220058585A/en unknown
- 2020-09-04 CA CA3152990A patent/CA3152990A1/en active Pending
- 2020-09-04 JO JOP/2022/0058A patent/JOP20220058A1/en unknown
- 2020-09-04 PE PE2022000372A patent/PE20221051A1/en unknown
- 2020-09-04 WO PCT/IB2020/058250 patent/WO2021044360A1/en active Application Filing
- 2020-09-04 EP EP20768409.3A patent/EP4025238A1/en active Pending
- 2020-09-04 WO PCT/IB2020/058252 patent/WO2021044362A1/en unknown
- 2020-09-04 US US17/640,295 patent/US20230220048A1/en active Pending
- 2020-09-04 KR KR1020227010907A patent/KR20220058588A/en unknown
- 2020-09-04 BR BR112022003745A patent/BR112022003745A2/en unknown
- 2020-09-04 BR BR112022003762A patent/BR112022003762A2/en unknown
- 2020-09-04 AR ARP200102479A patent/AR119902A1/en unknown
- 2020-09-04 JP JP2022514568A patent/JP2022547050A/en active Pending
- 2020-09-04 JP JP2022514843A patent/JP2022547111A/en active Pending
- 2020-09-04 US US17/640,293 patent/US20230265160A1/en active Pending
- 2020-09-04 CU CU2022000015A patent/CU20220015A7/en unknown
- 2020-09-04 CU CU2022000016A patent/CU20220016A7/en unknown
- 2020-09-04 AR ARP200102483A patent/AR119905A1/en unknown
- 2020-09-04 JO JOP/2022/0055A patent/JOP20220055A1/en unknown
- 2020-09-04 KR KR1020227010892A patent/KR20220058586A/en unknown
- 2020-09-04 MX MX2022002637A patent/MX2022002637A/en unknown
- 2020-09-04 CN CN202080061631.8A patent/CN114302896A/en active Pending
- 2020-09-04 EP EP20768408.5A patent/EP4025237A1/en active Pending
- 2020-09-04 CN CN202080061452.4A patent/CN114341194A/en active Pending
- 2020-09-04 PE PE2022000365A patent/PE20220401A1/en unknown
- 2020-09-04 CN CN202080061624.8A patent/CN114341195A/en active Pending
- 2020-09-04 CA CA3152500A patent/CA3152500A1/en active Pending
- 2020-09-04 AU AU2020343512A patent/AU2020343512A1/en active Pending
- 2020-09-04 EP EP20768410.1A patent/EP4025239A1/en active Pending
- 2020-09-04 US US17/640,291 patent/US20230308835A1/en active Pending
- 2020-09-04 MX MX2022002638A patent/MX2022002638A/en unknown
- 2020-09-04 CR CR20220089A patent/CR20220089A/en unknown
- 2020-09-04 AU AU2020343926A patent/AU2020343926A1/en active Pending
- 2020-09-04 AU AU2020340618A patent/AU2020340618A1/en active Pending
- 2020-09-04 TW TW109130528A patent/TW202122414A/en unknown
- 2020-09-04 JP JP2022514570A patent/JP2022547051A/en active Pending
- 2020-09-04 CA CA3152499A patent/CA3152499A1/en active Pending
- 2020-09-04 WO PCT/IB2020/058251 patent/WO2021044361A1/en active Application Filing
- 2020-09-07 TW TW109130667A patent/TW202122415A/en unknown
-
2022
- 2022-02-11 ZA ZA2022/01827A patent/ZA202201827B/en unknown
- 2022-02-11 ZA ZA2022/01828A patent/ZA202201828B/en unknown
- 2022-02-14 IL IL290618A patent/IL290618A/en unknown
- 2022-02-16 IL IL290675A patent/IL290675A/en unknown
- 2022-02-16 IL IL290660A patent/IL290660A/en unknown
- 2022-03-03 EC ECSENADI202216180A patent/ECSP22016180A/en unknown
- 2022-03-03 CO CONC2022/0002545A patent/CO2022002545A2/en unknown
- 2022-03-03 CO CONC2022/0002567A patent/CO2022002567A2/en unknown
- 2022-03-04 EC ECSENADI202216558A patent/ECSP22016558A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003762A2 (en) | Therapeutic fusion proteins | |
| BR112018003898A2 (en) | auxiliary material for application to colon tissue | |
| BR112015009948A8 (en) | Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders | |
| BR112015012197A8 (en) | cdk mtor inhibitor uses, and pharmaceutical combination comprising the same | |
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| BR112016015818A2 (en) | COMPOUNDS AND THEIR USES FOR TREATMENT OF PATIENTS WITH ROS1-MUTANTED CANCER CELLS | |
| BR112015020787A2 (en) | quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| BR112017018872A2 (en) | combination of a pd-1 antagonist and eribulin for cancer treatment | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| BR112021015109A2 (en) | Dual drug-linker conjugate and use | |
| BR112016029067A2 (en) | "compound, pharmaceutical composition, and methods for inhibiting the renal external medullary potassium channel, for causing diuresis, natriuresis or both and for treating one or more disorders". | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| EA201790563A8 (en) | APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY | |
| BR112021018262A2 (en) | Treatment of associated mitochondrial diseases and disorders, including symptoms thereof using pridopidine | |
| BR112015021265A2 (en) | enhancement methods of use for recombinant human secretoglobins | |
| BR112016015997A2 (en) | ? PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND 15- HEPE AND METHODS TO TREAT ASTHMA AND PULMONARY DISORDERS WITH THE USE OF THEM? | |
| BR112019006174A2 (en) | therapeutic protein | |
| EA201691656A2 (en) | THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS | |
| BR112019018028A2 (en) | COMPOUND, COMBINATION, E. USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME | |
| BR112017021669A2 (en) | oral pharmaceutical formulations, method for treating diseases and use of said formulations | |
| BR112022009066A2 (en) | EZETIMIBA FOR USE IN CANCER TREATMENT | |
| MA39448B1 (en) | (r) -pirlindole and its pharmaceutically acceptable salts for medical use | |
| WO2016066722A3 (en) | Bacteriophage combinations for human or animal therapy | |
| BR112017019824A2 (en) | compounds; pharmaceutical composition; method for prophylactic or therapeutic treatment of fibrosis in a subject; uses of a compound; method for preventing, reducing or delaying fat accumulation in a subject's liver; method for preventing, reducing or delaying renal tubular cell death in a subject; and method for restoring normal tissue architecture in a subject | |
| BR112021016102A2 (en) | fcmr binding molecules and uses thereof |